Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction (TAYSIDE Trial)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Will metformin improve exercise capacity in chronic heart failure patients who has insulin resistance (pre-diabetic- means before they become diabetic)?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT00736385

Fatty Liver

TERMINATED PHASE4

Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease

NCT06932874

Atherosclerotic Heart Disease Type 2 Diabetes

RECRUITING PHASE4

Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes

NCT01690091

Insulin Resistance Chronic Heart Failure

COMPLETED PHASE2/PHASE3

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

NCT00546728

Impaired Glucose Tolerance

COMPLETED PHASE4

Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance

NCT00667498

Pediatric Obesity Insulin Resistance Hyperinsulinemia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Exercise incapacity is one of the major debilitating symptoms of heart failure patients. Studies showed that heart failure patients will become insulin resistance (IR) or vice versa, severity of heart failure also correlates with the severity of insulin resistance. A recent study demonstrated that if we correct diabetic patient insulin resistance by giving them a drug to make them more sensitive to the effects of insulin, their exercise capacity improves. Therefore, we think that the same effects might happen in heart failure patients who have been identified to the insulin resistance by blood test. Insulin resistance means that they have not yet become diabetic and it is a stage the diabetic patients go through before they develop diabetes.

Therefore, we plan to use a drug called metformin (a diabetic drug), give it to heart failure patients who also have IR for 4 months and examine the effects before and after 4 months of treatment. It is a double blind control study, therefore, neither the examiner nor the patient know which drug they receive (either active drug- Metformin, or a placebo).

The main objective is to assess their exercise capacity using an exercise test called Innocor System. It is a bicycle based exercise test that involves patient breathing into a mouth piece before and during exercise in order for the machine to work out the maximum oxygen consumption and pumping power of the heart.

The other objectives of the trial are looking at the possible mechanisms of improving exercise capacity. We aim to answer the following questions by doing the following tests:

Does exercise capacity improve because of

1. The effect of metformin on the heart? We will answer this question by doing an ultrasound scan of the heart (Echocardiography)
2. The effects on the blood vessels? We plan to perform a test called flow-mediated dilatation, it is an ultrasound scan of the artery in the arm and also assess the blood flow in the skin using a test called Laser Doppler scan (small amount of medication will be delivered through a small electric current and the blood vessels response will be assessed using the laser doppler scan)
3. The effects on the muscle? We will do a muscle biopsy looking at the enzymes activities in the muscle before and after taking 4 months of medication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congestive Heart Failure Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Receiving Metformin for 4 months

Group Type ACTIVE_COMPARATOR

Metformin

Intervention Type DRUG

Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks

2

Matched Placebo for 4 months

Group Type PLACEBO_COMPARATOR

Matched Placebo (Capsules)

Intervention Type DRUG

Similar dosing regime as active comparator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin

Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks

Intervention Type DRUG

Matched Placebo (Capsules)

Similar dosing regime as active comparator

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 25-80 yrs with compensated CHF in NYHA functional I-III with evidence of insulin resistance \[fasting insulin resistance index values of \> 2.7 are said to have insulin resistance\].
* Documented Left ventricular systolic dysfunction or LV ejection fraction \< 35%

Exclusion Criteria

* Elderly patients (aged \>80 yrs);
* Patients with decompensated CHF (NYHA functional class IV and /or signs of decompensated CHF);
* Renal dysfunction (serum creatinine \> 160 mmol/L);
* Patients who are unable to exercise including patients that will be excluded for reasons of safety or potential effects on exercise performance. Therefore, patients with angina or other cardiac or pulmonary symptoms potentially limiting exercise performance will be excluded.
* Systolic blood pressure \>190 mmHg at rest or \>250 mmHg with exercise or diastolic blood pressure \>95 mmHg at rest or \>105 mmHg with exercise will also be a reason for exclusion;
* Patients with underlying disease likely to limit life span and/or increase risk of interventions will be excluded i.e., cancer; cardiovascular disease .i.e., uncontrolled hypertension: SBP\>180 mmHg or DBP, recent stroke, any severe chronic disease (including renal and hepatic disease).

Minimum Eligible Age

25 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No